Selective ophthalmic artery infusion chemotherapy for advanced intraocular retinoblastoma: CCHMC early experience

Samantha T. Michaels; Todd A. Abruzzo; James J. Augsburger; Zélia M. Correâ; Adam Lane; James I. Geller

doi:10.1097/MPH.0000000000000471

Selective ophthalmic artery infusion chemotherapy for advanced intraocular retinoblastoma: CCHMC early experience

Samantha T. Michaels, Todd A. Abruzzo, James J. Augsburger, Zélia M. Correâ, Adam Lane, James I. Geller

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Selective ophthalmic artery infusion chemotherapy (SOAIC) is increasingly used to treat retinoblastoma. We report the toxicities and outcome of 19 eyes in 17 patients with retinoblastoma receiving SOAIC treatment between 2008 and 2013. From the 87 treatments, mild local reactions were common. Myelosuppression was more common after triple-agent SOAIC (melphalan, carboplatin, and topotecan) than single-agent melphalan. Ocular salvage was achieved in 11 of 19 eyes and associated with triple-agent therapy. SOAIC is a effective therapy for some retinoblastoma with manageable toxicity; however, systemic toxicity increases with increasing therapeutic intensity of SOAIC.

Original language	English (US)
Pages (from-to)	65-69
Number of pages	5
Journal	Journal of Pediatric Hematology/Oncology
Volume	38
Issue number	1
DOIs	https://doi.org/10.1097/MPH.0000000000000471
State	Published - 2016
Externally published	Yes

Keywords

Retinoblastoma
Selective ophthalmic artery infusion chemotherapy
Vitreal seeds

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1097/MPH.0000000000000471

Cite this

@article{5687c497a7944fd286d48bf9066fb19f,

title = "Selective ophthalmic artery infusion chemotherapy for advanced intraocular retinoblastoma: CCHMC early experience",

abstract = "Selective ophthalmic artery infusion chemotherapy (SOAIC) is increasingly used to treat retinoblastoma. We report the toxicities and outcome of 19 eyes in 17 patients with retinoblastoma receiving SOAIC treatment between 2008 and 2013. From the 87 treatments, mild local reactions were common. Myelosuppression was more common after triple-agent SOAIC (melphalan, carboplatin, and topotecan) than single-agent melphalan. Ocular salvage was achieved in 11 of 19 eyes and associated with triple-agent therapy. SOAIC is a effective therapy for some retinoblastoma with manageable toxicity; however, systemic toxicity increases with increasing therapeutic intensity of SOAIC.",

keywords = "Retinoblastoma, Selective ophthalmic artery infusion chemotherapy, Vitreal seeds",

author = "Michaels, {Samantha T.} and Abruzzo, {Todd A.} and Augsburger, {James J.} and Corre{\^a}, {Z{\'e}lia M.} and Adam Lane and Geller, {James I.}",

year = "2016",

doi = "10.1097/MPH.0000000000000471",

language = "English (US)",

volume = "38",

pages = "65--69",

journal = "Journal of Pediatric Hematology/Oncology",

issn = "1077-4114",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Selective ophthalmic artery infusion chemotherapy for advanced intraocular retinoblastoma

T2 - CCHMC early experience

AU - Michaels, Samantha T.

AU - Abruzzo, Todd A.

AU - Augsburger, James J.

AU - Correâ, Zélia M.

AU - Lane, Adam

AU - Geller, James I.

PY - 2016

Y1 - 2016

N2 - Selective ophthalmic artery infusion chemotherapy (SOAIC) is increasingly used to treat retinoblastoma. We report the toxicities and outcome of 19 eyes in 17 patients with retinoblastoma receiving SOAIC treatment between 2008 and 2013. From the 87 treatments, mild local reactions were common. Myelosuppression was more common after triple-agent SOAIC (melphalan, carboplatin, and topotecan) than single-agent melphalan. Ocular salvage was achieved in 11 of 19 eyes and associated with triple-agent therapy. SOAIC is a effective therapy for some retinoblastoma with manageable toxicity; however, systemic toxicity increases with increasing therapeutic intensity of SOAIC.

AB - Selective ophthalmic artery infusion chemotherapy (SOAIC) is increasingly used to treat retinoblastoma. We report the toxicities and outcome of 19 eyes in 17 patients with retinoblastoma receiving SOAIC treatment between 2008 and 2013. From the 87 treatments, mild local reactions were common. Myelosuppression was more common after triple-agent SOAIC (melphalan, carboplatin, and topotecan) than single-agent melphalan. Ocular salvage was achieved in 11 of 19 eyes and associated with triple-agent therapy. SOAIC is a effective therapy for some retinoblastoma with manageable toxicity; however, systemic toxicity increases with increasing therapeutic intensity of SOAIC.

KW - Retinoblastoma

KW - Selective ophthalmic artery infusion chemotherapy

KW - Vitreal seeds

UR - http://www.scopus.com/inward/record.url?scp=84952865035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952865035&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000000471

DO - 10.1097/MPH.0000000000000471

M3 - Article

C2 - 26583615

AN - SCOPUS:84952865035

SN - 1077-4114

VL - 38

SP - 65

EP - 69

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

IS - 1

ER -

Selective ophthalmic artery infusion chemotherapy for advanced intraocular retinoblastoma: CCHMC early experience

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this